BMS-986446

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Alzheimer Disease, Early OnsetAlzheimer's DiseaseHealthy Participants

Phase 1

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

CompletedNCT06084598

Bristol-Myers SquibbHealthy Participants

Start: 2023-10-12End: 2024-03-08Updated: 2024-03-15

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Not yet recruitingNCT07780383

Bristol-Myers SquibbAlzheimer's Disease, Healthy Participants

Start: 2026-08-21End: 2027-06-17Target: 84Updated: 2026-08-21

Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Active, not recruitingNCT06268886

Bristol-Myers SquibbAlzheimer Disease, Early Onset

Start: 2024-03-20End: 2027-03-18Target: 310Updated: 2025-07-24

Related Papers

TargetTau-1: A Phase II Trial Evaluating the Efficacy, Safety, and Tolerability of a Monoclonal Antibody Targeting the Tau Protein Microtubule Binding Region in Patients with Early Alzheimer’s Disease

EMJ Neurology2025-02-11

TargetTau‐1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS‐986446, an anti‐MTBR tau monoclonal antibody, in patients with early Alzheimer’s disease

Alzheimer s & Dementia2024-12-013 citations